Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Breast cancer is the second leading cause of cancer deaths among women. Multiple microRNAs (miRNAs) have been reported to be associated with breast cancer progression or metastasis. The purpose of the current study was to identify plasma extracellular miRNAs associated with incident breast cancer. Levels of 166 plasma miRNA were measured using qRT-PCR in 2140 Framingham Heart Study female participants with a median follow up of 15.7 years. Prospective analyses of the associations of miRNAs with the occurrence of 56 new-onset breast cancer events were conducted using proportional hazards regression. The expression levels miR-134-5p (P=0.002) and miR-505-3p (P=0.005) were found to be positively associated with incident breast cancer after adjusting for age, body mass index, and cigarette smoking. These results highlight plasma miRNAs as potential biomarkers of breast cancer risk. Validation of these findings in larger and more diverse cohorts is warranted.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11626277 | PMC |
| http://dx.doi.org/10.62347/KMFI7371 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Broad-Spectrum Antibiotic Use at the End of Life in Patients With Advanced Cancer.
JAMA Netw Open
September 2025
Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, South Korea.
Importance: Patients with advanced cancer frequently receive broad-spectrum antibiotics, but changing use patterns across the end-of-life trajectory remain poorly understood.
Objective: To describe the patterns of broad-spectrum antibiotic use across defined end-of-life intervals in patients with advanced cancer.
Design, Setting, And Participants: This nationwide, population-based, retrospective cohort study used data from the South Korean National Health Insurance Service database to examine broad-spectrum antibiotic use among patients with advanced cancer who died between July 1, 2002, and December 31, 2021.
Association Between Levonorgestrel-Releasing Intrauterine System Exposure Duration and Breast Cancer Incidence.
Obstet Gynecol
July 2025
Graduate School of Medicine, University of Wollongong, Wollongong, New South Wales, Australia.
NPY-functionalized niosomes for targeted delivery of margatoxin in breast cancer therapy.
Med Oncol
September 2025
Venom and Biotherapeutics Molecules Laboratory, Biotechnology Department, Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran.
Neuropeptide Y (NPY) and the voltage-gated potassium channel Kv1.3 are closely associated with breast cancer progression and apoptosis regulation, respectively. NPY receptors (NPYRs), which are overexpressed in breast tumors, contribute to tumor growth, migration, and angiogenesis.
View Article and Find Full Text PDFS100A8/A9-MCAM signaling promotes gastric cancer cell progression via ERK-c-Jun activation.
In Vitro Cell Dev Biol Anim
September 2025
Department of Cell Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Kita-ku, Okayama-shi, Okayama, 700-8558, Japan.
S100 protein family members S100A8 and S100A9 function primarily as a heterodimer complex (S100A8/A9) in vivo. This complex has been implicated in various cancers, including gastric cancer (GC). Recent studies suggest that these proteins play significant roles in tumor progression, inflammation, and metastasis.
View Article and Find Full Text PDFClinical-pathological patterns and prognosis of young women with breast cancer brain metastases: a single-center retrospective study.
J Neurooncol
September 2025
Sunnybrook Research Institute, University of Toronto, Toronto, ON, Canada.
Purpose: Breast cancer (BC) is the most frequent cancer among women and the second leading cause of central nervous system (CNS) metastases. While the epidemiology of CNS metastases from BC has been well described, little is known about the treatment patterns and outcomes of young women < 40 years of age with BC that is metastatic to the CNS.
Methods: In this retrospective analysis, we identified patients with metastatic breast cancer (MBC) to the CNS who were treated at the Sunnybrook Odette Cancer Center, Toronto, Canada between 2008 and 2018.